| Product Name | Licoricidin |
|---|---|
| CAS | 30508-27-1 |
| Formula | C26H32O5 |
| MW | 424.53 |
| Appearance | |
| Melting point | 161.0-162.5 °C |
| Boiling point | 610.8±55.0 °C | Condition: Press: 760 Torr |
| PKa | 10.10±0.40 | Condition: Most Acidic Temp: 25 °C |
| Product Name | Licoricidin |
|---|---|
| CAS | 30508-27-1 |
| Formula | C26H32O5 |
| MW | 424.53 |
| Appearance | |
| Melting point | 161.0-162.5 °C |
| Boiling point | 610.8±55.0 °C | Condition: Press: 760 Torr |
| PKa | 10.10±0.40 | Condition: Most Acidic Temp: 25 °C |
WKQ-0001822
中文名稱：甘草西定
英文名稱：Licoricidin
英文別名：1,3-Benzenediol, 4-[(3R)-3,4-dihydro-7-hydroxy-5-methoxy-6-(3-methyl-2-butenyl)-2H-1-benzopyran-3-yl]-2-(3-methyl-2-butenyl)- (9CI);1,3-Benzenediol, 4-[3,4-dihydro-7-hydroxy-5-methoxy-6-(3-methyl-2-butenyl)-2H-1-benzopyran-3-yl]-2-(3-methyl-2-butenyl)-, (R)-;2',4',5-Isoflavantriol, 7-methoxy-3',6-bis(3-methyl-2-butenyl)- (8CI);4-[(3R)-3,4-Dihydro-7-hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-2H-1-benzopyran-3-yl]-2-(3-methyl-2-buten-1-yl)-1,3-benzenediol;(+)-Licoricidin;7-O-Demethyllicorisoflavan A;Licoricidin;Licorisoflavan B;
分子式：C26H32O5
分子量：424.53
CAS號(hào)：30508-27-1
純度：HPLC≥98%
熔點(diǎn)：161.0-162.5 °C
沸點(diǎn)：610.8±55.0 °C | Condition: Press: 760 Torr
密度：1.171±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：10.10±0.40 | Condition: Most Acidic Temp: 25 °C
儲(chǔ)存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標(biāo)準(zhǔn)品和天然植物有效單體，主打中藥對(duì)照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請(qǐng)關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
| In vitro investigation of permeability and metabolism of licoricidin | ||
| Source:SCI：LIFE SCIENCES | Author:Lina Shan | Notes：影響因子：3.448 |
| Reference description | ||
Licoricidin (>98%) was purchased from Sichuan Weikeqi Biotechnology Co., Ltd. (Sichuan, China). We have described the probe substrates, probe substrate metabolites, and positive inhibitors of CYP isoforms in our previous paper [10]. Naproxen, furosemide, 1-aminobenzotriazole (ABT), phenacetin, sulfaphenazole, chlorzoxazone, quinidine, clomethiazole, furafylline, diclofenac, dextromethorphan, ketoconazole, testosterone, (S)-mephenytoin, omeprazole, glucose-6-phosphate dehydrogenase, | ||
